T. A. Rozhkova

T. A. Rozhkova

Auto-generated profile, based on publicly available information

T. A. Rozhkova

Chazov National Medical Research Center of Cardiology, Moscow

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MYM. V. Yezhov
M. V. Yezhov
SBS. A. Bliznyuk
S. A. Bliznyuk
NTNarek Tmoyan
Narek Tmoyan
TRT. A. Rozhkova
T. A. Rozhkova
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
ТКТ. Ю. Кузнецова
Т. Ю. Кузнецова
Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС)

24 April 2023 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
Uliana V ChubykinaUliana V Chubykina
Uliana V Chubykina
Marat EzhovMarat Ezhov
Marat Ezhov
TRT.A. Rozhkova
T.A. Rozhkova
BTB.M. Tamaeva
B.M. Tamaeva
ASA.A. Sokolov
A.A. Sokolov
SBS.E. Bednova
S.E. Bednova
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить комплаентность пациентов с гетерозиготной семейной гиперхолестеринемией (геСГХС) в течение 5-летнего периода работы регистра РЕНЕССАНС (Регистр пациентов с СГХС и пациентов очень высокого сЕрдечно-Сосудистого риска с недоСтАточной эффективНоСтью, проводимой гиполипидемической терапии). МАТЕРИАЛ И МЕТОДЫ РЕНЕССАНС является открытым, национальным, наблюдательным исследованием и включает больных с СГХС. Проводилась оценка факторов риска атеросклероза, анамнеза сердечно-сосудистых заболеваний (ССЗ), интенсивности гиполипидемической терапии (ГЛТ). Каждому пациенту определены уровни общего холестерина, триглицеридов, холестерина липопротеидов высокой плотности в сыворотке крови. Содержание холестерина липопротеидов низкой плотности (ХС ЛНП) рассчитывали по формуле Фридвальда. РЕЗУЛЬТАТЫ В исследование включено 2317 пациентов с геСГХС, из которых 58% — женщин. При включении в регистр 59% больных относились к категории высокого сердечно-сосудистого риска. Динамический визит проведен у 47% пациентов, период наблюдения составил 24 [11; 42] мес. Больные с динамическим визитом чаще имели определенный диагноз геСГХС и отягощенный наследственный анамнез по ССЗ, были моложе и им в более раннем возрасте диагностировали СГХС (p<0,05). У пациентов без динамического визита были распространены модифицируемые факторы риска (p<0,001). Среди пациентов высокого сердечно-сосудистого риска 54% больных получали ГЛТ, очень высокого — 86%. За время наблюдения в регистре доля принимающих ГЛТ пациентов увеличилась с 59 до 78%, в том числе статинами в режиме высокой интенсивности с 36 до 54%, в комбинации с эзетимибом — с 15 до 34%, ингибиторами PCSK9 — с 4 до 14% (p<0,001 для всех). Целевого уровня ХС ЛНП достигли 13% пациентов. Данные симуляционного анализа продемонстрировали, что для адекватного контроля уровня ХС ЛНП, не менее 92,5% больных с геСГХС в регистре должны получать трехкомпонентную ГЛТ со статинами, эзетимибом и ингибиторами PCSK9. ЗАКЛЮЧЕНИЕ 5-летнее наблюдение за участниками регистра РЕНЕССАНС демонстрирует увеличение использования многокомпонентных схем лечения, но недостаточное для адекватного контроля ХС ЛНП.

22 August 2025 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
IAI Alekseeva
I Alekseeva
Uliana V ChubykinaUliana V Chubykina
Uliana V Chubykina
Marat EzhovMarat Ezhov
Marat Ezhov
ATA Tyurina
A Tyurina
TKT Kolmakova
T Kolmakova
NBN Bizyaeva
N Bizyaeva
Aim. To study the adequacy and effectiveness of lipid-lowering therapy (LLT) prescribed to patients with heterozygous familial hypercholesterolemia (HeFH), including fixed-dose combinations (FDC) of rosuvastatin with ezetimibe, as well as the frequency of achieving target low-density lipoprotein cholesterol (LDL-C) levels.Material and methods. The clinical and demographic data of 3151 patients with HeFH at high or very high cardiovascular risk from the RENAISSANCE registry were retrospectively analysed. Among the 1612 individuals receiving LLT, 477 patients were treated with a combination of rosuvastatin at various doses and ezetimibe 10 mg daily, either as a free combination or as a FDC.Results. The median age of the patients was 46.0 [32.0; 57.0] years. The median LDL-C level was 6.4 [5.3; 7.8] mmol/L. Although LLT was recommended to all participants, approximately half (49%, n=1539) were not receiving treatment. Among the 1612 patients on LLT, 44% (n=703) received statin monotherapy, and 43% (n=697) were treated with a combination of statins and ezetimibe. Of the 477 patients taking rosuvastatin with ezetimibe, the majority were active adults of working age (35-64 years): 335 (80%) vs 86 (20%), p <0.05. Most patients preferred taking rosuvastatin with ezetimibe in the FDC: 357 (74.8%) vs 120 (25.2%), p <0.05. Among those on FDC, a significantly higher proportion used Zenon® compared to other FDCs: 44.4% (n=212) vs 30.4% (n=145), p <0.05. A significant reduction in LDL-C was observed compared to baseline: 61% in the free combination group and 65% in the FDC group, including a 67% reduction in the Zenon® subgroup (p <0.001). The rate of achieving LDL-C targets among high/very high cardiovascular risk patients was lower in the free combination group compared to the FDC group, with the highest rates observed among Zenon® users: 5.8% (n=7), 17.9% (n=26), and 21.7% (n=46), respectively (p <0.01).Conclusion. Among patients with НeFH, the use of a FDC of rosuvastatin and ezetimibe is associated with higher treatment adherence and a greater likelihood of achieving target LDL-С levels.

24 April 2026 in Kardiologiia
Verified
Journal Article
Closed access
Uliana V ChubykinaUliana V Chubykina
Uliana V Chubykina
Marat EzhovMarat Ezhov
Marat Ezhov
TRT. A. Rozhkova
T. A. Rozhkova
ATA. V. Tyurina
A. V. Tyurina
ASA. A. Sokolov
A. A. Sokolov
PVPetr Vasilev
Petr Vasilev
Aim To evaluate the clinical, demographic, and molecular genetic characteristics of patients with homozygous familial hypercholesterolemia (HoFH), as well as the effectiveness of lipid-lowering therapy and the incidence of cardiovascular complications, based on the RENAISSANCE registry (Registry of patiENts with FH and very high cArdIovaScular riSk pAtients with iNuffiCient rEsponse to lipid-lowering therapy). Material and methods             The RENAISSANCE registry is an open-label, national observational study involving patients with FH. The diagnosis of HoFH was established according to the 2014 European Atherosclerosis Society criteria. The study accounted for atherosclerosis risk factors, physical examination findings, cardiovascular history, and current lipid-lowering therapy. Lipid profile parameters included concentrations of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a). Most patients underwent genetic testing for hypercholesterolemia. The study's endpoint comprised fatal and non-fatal cardiovascular events. Results The study included 6 children and 13 adults (6 males) with HoFH. The mean age was 26±14 years; an average follow-up period in the registry was 5.3±2.8 years. Tendon xanthomas were observed in 68% of patients, cutaneous xanthomas in 74%, and corneal arcus in 47%. The mean age of cardiovascular disease onset was 22 ± 8 years. Ischemic heart disease was diagnosed in 63% of patients, and 47% had undergone cardiovascular interventions (arterial revascularization, aortic valve replacement). The mortality rate reached 21%. Peak LDL-C level was 17.7±4.0 mmol/L. By the final visit, LDL-C had decreased by 46% to 9.6±5.6 mmol/L, though only four patients (21%) achieved an LDL-C level ≤3 mmol/L. The median lipoprotein(a) concentration was 100 [27; 145] mg/dL, with elevated levels (≥30 mg/dL) identified in 10 patients (67%). Treatment regimens included statins (95%), ezetimibe (95%), PCSK9 inhibitors (37%), and lomitapide (21%); 53% of patients underwent lipoprotein apheresis. During the follow-up period, 14 cardiovascular events occurred across 7 patients (including one child): 4 coronary artery bypass grafts, 6 aortic valve replacements, and 4 deaths. Conclusion In the registry-based observational study of patients with HoFH, there was an increase in the use of complex combination therapies, including lipoprotein apheresis and lomitapide. However, reaching target LDL-C levels remains challenging, and the incidence of cardiovascular complications remains high.